כניסת משתמש
  |   
5909*
ייעוץ ורישום:
  
מדור רישום5909*

פרופ' בנימין שרדני

   
   
דוא"ל srednib@mishpat.ac.il

תחומי מחקר

טיפולים חדשים בסרטן, במחלות אוטו אימוניות, ובמחלות ניווניות.

השכלה

תאר שלישי Ph.D. 1978, אוניברסיטת בר-אילן, מיקרוביולוגיה/אימונולוגיה. בציון מעולה.
תאר שני M.Sc. 1973, אוניברסיטת בר-אילן, כימיה אורגנית (בהצטיינות)
תאר ראשון B.Sc. 1969, אוניברסיטת בר-אילן, כימיה

תפקידים ומשרות

2017-2012 נשיא המרכז האקדמי שערי מדע ומשפט
מ-2012 חבר האקדמיה הלאומית למדעים, מכסיקו
מ-2011 חבר הועדה המדעית של מרכז פלזנשטיין למחקר, קמפוס רבין
2010-2011 מייסד ודקאן של בית הספר ללימודים מתקדמים, אוניברסיטת בר-אילן
2008-2010 המדען הראשי של משרד הבריאות
2006-2011 ראש הועדה לתואר שלישי, אוניברסיטת בר-אילן
מ-1990 פרופסור מן המנין בפקולטה למדעי החיים, אוניברסיטת בר-אילן
מ-1990 ראש המכון לחקר הסרטן, איידס ואימונולוגיה, אוניברסיטת בר-אילן
2005-2006 מדען אורח במעבדה לאימונולוגיה, NIH, NIA, בתסדה, ארה"ב
2000-2001 מדען אורח במעבדה לאימונולוגיה, NIH, בתסדה, ארה"ב
1995-2004 מדען ראשי בחברה למחקר ולפיתוח, בר-אילן
1992-1994 מדען אורח במעבדה לאימונולוגיה, NEI, NIH, בתסדה, ארה"ב
1989-1991 דקאן הפקולטה למדעי הטבע ומתמטיקה, אוניברסיטת בר-אילן
1990-2013 חבר הסנאט, אוניברסיטת בר-אילן
1985-1987 עמית מחקר במעבדה לאימונולוגיה, NEI, NIH, בתסדה, ארה"ב
1984-1989 פרופסור חבר, המחלקה למדעי החיים, אוניברסיטת בר-אילן
1981-1984 מרצה בכיר, המחלקה למדעי החיים, אוניברסיטת בר-אילן
1980-1981 מרצה בכיר במעבדה לאימונולוגיה, , NIHבתסדה, ארה"ב
1979-1980 עמית מחקר במעבדה לאימונולוגיה, המכון הלאומי לאלרגיה ולמחלות זיהומיות  NIH, בתסדה, ארה"ב
1973-1979 מדריך במחלקה למדעי החיים, אוניברסיטת בר-אילן
1970-1973 עוזר הוראה במחלקה לכימיה אורגנית, אוניברסיטת בר-אילן

פעילות אקדמית נוספת

מ-2011 עורך אורח, כתב העת Seminars in Cancer Biology
מ-2010 חבר הועדה המדעית, מרכז פלזנשטיין למחקר רפואי
מ-2008 חבר הועדה המדעית, האגודה הישראלית לחקר הסרטן
מ-2000 חבר הועדה המדעית, הפורום הבינלאומי למיקרו-סביבה ICMF) 2006-2008) : נשיא האגודה הישראלית לאימונולוגיה

פרסים ומענקי מחקר

  • פרס פנחס ספיר למחקר
  • פרס מיכל לנדאו למחקר
  • פרס רוטשילד למחקר
  • מלגת אלון
  • ציטוט בפרזנטציה של זוכה פרס נובל, פרופ' בן-אסרף (1981)
  • ראש הקדתרה על שם איזידורה מוסקוביץ'
  • קרן על שם דורשה וולמן
  • קרן מחקר לחקר הסרטן על שם פרידה שטולמן
  • קרן רוברט אסרף
  • ראש ועדת הפרס לחקר הסרטן על שם דר' טובי קומט ולרשטיין
  • קרן מתכנית שיפמן למחקר גלובלי בין ישראל וה-NIH
  • קרן תכנית פטר לחקר הסרטן

חברות באגודות מדעיות

  • האקדמיה למדעים, מכסיקו
  • נשיא האגודה לאימונולוגיה, ישראל
  • האגודה לחקר הסרטן, ישראל
  • החברה הישראלית לביוכימיה ולביולוגיה מולקולרית
  • אגודת האימונולוגים, ארה"ב (AAI)
  • האגודה האמריקנית להמטולוגיה ((ASH
  • האגודה האמריקנית לחקר הסרטן (AACR)
  • האגודה האמריקנית לקידום המדע
  • החברה הבינלאומית להמטלוגיה ניסויית (ISEH)
  • החברה הבינלאומית לחיסון טבעי
  • החברה הבינלאומית לאיידס (IAS)
  • הפדרציה של מדענים ישראליים לביולוגיה ניסויית
  • החברה הבינלאומית ל-CELL DEATH
  • החברה הישראלית לחקר הסרטן

תפקידים נוספים

1982-1984 חבר מערכת בכתב העת Experimental Hematology
מ-1987 חבר מערכת בכתב העת Natural Immunity & Cell Growth Regulation
מ-1988 עורך משנה בכתב העת Future Trends in Research on AIDS, Cancer and Therapies, Natural Immunity and Cell Growth Regulatio
מ-1990 עורך משנה בכתב העת International Symposium on AIDS and Cancer, Natural Immunity and Cell Growth Regulatio

פטנטים

  • מחזיק ב-28 פטנטים על תרכובות טלוריום בפעילות אימונו-מודולוטורית.

הוראה במרכז האקדמי שערי מדע ומשפט

  • מבוא למדעי הבריאות

פרסומים

Articles

  1. Sredni B. and Braverman S. Different rearrangements of benzylic trichloromethane sulfenates to sulfoxides and chlorides. Israel J. Chem. 8:30, 1970.
  2. Sredni B. and Pinchas S. The proton chemical shift of neat H2O. J. Mag. Res. 7:289, 1972.
  3. Braverman S. and Sredni B. The rearrangement of benzylic trichlormethane-sulfenates to sulfoxide and chlorides. Tetrahedron 30:2379, 1974.
  4. Sredni B., Kalechman I., Michlin H. and Rozenszajn L.A. Development of colonies in vitro of mitogen-stimulated mouse T lymphocytes. Nature 259:130, 1976.
  5. Sredni B. and Rozenszajn L.A. Inhibitory effect on growth of lymphocyte colonies by an active component derived from monocyte/macrophage cells. Exp. Hemat. 4:33, 1976.
  6. Rozenszajn L.A., Michlin H., Kalechman Y. and Sredni B. Colony growth in vitro of mitogen-stimulated mouse B lymphocytes. Immunology 32:319, 1977.
  7. Sredni B., Michlin H., Kalechman Y. and Rozenszajn L.A. Colony growth of mouse B lymphocytes induced by polyclonal B cell activators and Lip A component of lipopolysaccharide (LPS). Exp. Hemat. 5:53, 1977.
  8. Sredni B., Michlin H., Kalechman Y. and Rozenszajn L.A. Regulatory effects of macrophage-secreted factors on T lymphocyte colony growth. Cell. Immunol. 36:15, 1978.
  9. Sredni B. and Rozenszajn L.A. Relation between structure of bacterial lipopolysaccharide and the stimulation of B lymphocytes into colony formation. J. Cell. Physiol. 96:53, 1978.
  10. Shahin I., Grossman S. and Sredni B. Lipoxygenase-like enzyme in rat testes microsomes. Biochem. Biophys. Acta. 529:300, 1978.
  11. Sredni B., Michlin H., Kalechman Y. and Rozenszajn L.A. Regulatory effects of macrophage-secreted factors on T lymphocyte colony growth. Israel J. Med. Sci. 4:242, 1978.
  12. Sredni B., Gopas J. and Rozenszajn L.A. Induction of B-lymphocyte colonies in vitro by thumus-derived stimulating factor. Eur. J. Immunol. 8:681, 1978.
  13. Rozenszajn L.A., Zeevi A., Gopas J., Radnay J. and Sredni B. Lymphocyte  colony growth in vitro. In: Hematopoietic Cell Differentiation. p. 261, Academic Press, NY, 1978.
  14. Sredni B., Gopas J. and Rozenszajn L.A. Murine B lymphocyte colony formation induced in vitro by a thymic factor. Exp. Hemat. 6:3, 1978.
  15. Grossman S., Shahin I. and Sredni B. Rat testes lipoxygenase-like enzyme: characterization of products on linoleic acid. Biochem. Biophys. Acta 572: 293, 1979.
  16. Sredni B., Tse H.Y. and Schwartz R.H. Cloning of antigen-specific MHC-restricted proliferating T lymphocytes. Fed. Proc. 39:803, 1980.
  17. Rozenszajn L.A., Zeevi A., Goldman I. and Sredni B. Characterization of monocyte and lymphocyte mediators modulating T lymphocyte colony formation. In: Biochemical Characterization of Lymphokines. Eds. A.L. de Weck, F. Kristensen & M. Landy, pp. 261-264, Academic Press, NY, 1980.
  18. 18.Rozenszajn L.A. and Sredni B. In vitro growth of colonies of mitogen-stimulated mouse T lymphocytes: I. Conditions affecting colony formation. II. Structure of colonies and component cells. Exp. Hemat. 8:494, 1980.
  19. *Sredni B., Tse H.Y. and Schwartz, R.H. Direct cloning and extended culture of antigen-specific MHC-restricted, proliferating T lymphocytes. Nature 283:581-583, 1980.
  20. .*Sredni B. and Schwartz R.H. Alloreactivity of an antigen-specific T cell clone. Nature 287:855-857, 1980.
  21. *Sredni B. and Schwartz, R.H. Antigen-specific, proliferating T lymphocytes clones. Metholology, specificity, MHC restriction and alloreactivity. Immunol. Rev. 54:187-223, 1981.
  22. Rozenszajn L.A., Goldman I., Kalechman Y., Michlin H., Sredni B., Zeevi A. and Shoham D.  T-lymphocyte colony growth in vitro: factors modulating clonal expansion. Immunol. Rev. 54:157, 1981.
  23. Bland C.E., Sredni B. and Metcalfe D.D. Direct cloning and extended culture of basophils from mouse bone marrow: Biochemical characterization of basophil proteoglycan. J. Allergy Clin. Immunol. 67, 1981.
  24. Sredni B., Tse H.Y., Chen C. and Schwartz R.H. Antigen-specific clones of proliferating T lymphocytes. I. Methodology, specificity and MHC restriction. J. Immunol. 126:341, 1981.
  25. Sredni B., Matis L.A., Lerner E.A., Paul W.E. and Schwartz R.H. Antigen-specific T cell clones restricted to unique F1 major histocompatibility complex determinants. J. Exp. Med. 153:677, 1981.
  26. Sredni B., Volkman D., Schwartz R.H. and Fauci A.S. Antigen-specific human T cell clones: development of clones requiring HLA-DR-compatible-presenting cells for stimulation in the presence of antigen. Proc. Natl. Acad. Sci., U.S.A. 78:1858, 1981.
  27. Metcalfe D.D., Bland C.E. and Sredni B. Comparison of proteoglycans synthesized during lymphocyte dependent mast cell and basophil proliferation. Fed. Proc. 40:1023, 1981.
  28. Rozenszajn L. A., Goldman I., Kalechman I., Michlin H., Sredni B., Zeevi A. and Shoham D. T-lymphocyte colony growth in vitro: factors modulating clonal expansion. Immunol. Rev. 54:157, 1981.
  29. Sredni B. and Schwartz R.H. Antigen-specific clones of proliferating T-lymphocytes. In: Experimental Hematology Today. Eds. S.J. Baum & A. Khan, S. Karger Press, p. 181, 1981.
  30. Paul W.E., Sredni B. and Schwartz R.H. Long-term growth and cloning of non-transformed lymphocytes. Review article, Nature 294:697, 1981.
  31. .Sredni B., Sieckmann D.G., Kumagai S. and Paul W.E. Long-term cloning of nontransformed human B-lymphocytes. Clin. Res. 29:377, 1981.
  32. Gorelik E., Kedar E., Sredni B. and Herberman, R. In vivo antitumor effects by local adoptive transfer of mouse and human culture lymphoid cells. Int. J. Cancer 28:157, 1981.
  33. Sredni B., Sieckmann D.G., Kumagai S., House S., Green I. and Paul W.E. Long-term culture and cloning of nontransformed human B lymphocytes. J. Exp. Med. 154:1500, 1981.
  34. Kedar E., Herberman R.B., Gorelik E., Sredni B., Bonnard G.D. and Navarro N. Antitumor reactivity in vitro and in vivo of mouse and human lymphoid cells cultured with T cell growth factor. In: The Potential Role of T Cell Subpopulations in Cancer Therapy, Eds. A. Fefer and A. Goldstein, Raven Press, New York, pp. 173, 1982.
  35. Sredni B. Methods for long-term growth and cloning of T cells reactive with soluble antigens. J. Immunol. Methods 49:1, 1982.
  36. Kumagi S., Sredni B., House S., Steinberg A.D. and Green I. Defective regulation of B lymphocyte colony formation in patients with systemic lupus erythematosis. J. Immunol. 128:258, 1982.
  37. Sredni B., Volkman D., Schwartz R.H. and Fauci A.S. Human T cell clones reactive with soluble antigens: Methodology, specificity and MHC-restriction. In: Isolation, Characterization and Utilization of T Lymphocyte Clones. Eds. F.W. Fitch & G. Fathman. Academic Press, New York, p. 440, 1982.
  38. Kedar E., Ikejiri B.L., Sredni B., Bonavida B. and Herberman R.B. Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells. Cell. Immunol. 69:305, 1982.
  39. Schwartz R.H. and Sredni B. Alloreactivity of antigen-specific T cell clones. In: Isolation, Characterization and Utilization of T Lymphocyte Clones. Eds. F.W. Fitch & G. Fathman, Academic Press, New York, p. 375, 1982.
  40. .Paul W.E., DeFranco A., Sredni B. and Howard, M. Long term growth of B-lymphocytes. Ann. N.Y. Acad. Sci. 399:105, 1982.
  41. Sredni B. Establishment of colonies of antigen reactive human T cells. In: Isolation, Characterization and Utilization of T Lymphocyte Clones. Eds. F.W. Fitch & G. Fathman, Academic Press, New York, p. 535, 1982.
  42. Paul W.E., Sredni B. and Howard M. Cell cloning as a tool to analyze the immune response. In: Research Frontiers in Aging and Cancer. National Cancer Institute, Mon. 60:211, 1982.
  43. Volkman D.J., Sredni B., Mostowsky H., Fauci A.S. and Schwartz R.H. Demonstration of major histocompatibility complex restriction in man using an antigen-specific proliferating T cell clone. Stem. Cells 2:65, 1982.
  44. Sredni B., Friedman M., Bland C.E. and Metcalfe D.D. Ultrastructural, biochemical and functional characteristic of histamine-containing cells cloned from mouse bone marrow: Tentative identification as mucosal mast cells. J. Immunol. 131:915, 1983.
  45. Michlin H., Kalechman Y. and Sredni B. Normal human T-lymphocyte cell lines producing colony stimulating factor. Exp. Hemat. 11:204, 1983.
  46. Fishman P., Sredni B., Hart J. and Djaldeti M. Elemental X-ray microanalysis of mouse peritoneal and bone marrow derived cultured mast cells. Ann. Allergy 53: 70, 1984.
  47. Rozenszajn L.A., Radnay J., Nussenblatt R. and Sredni B. Human lymphoid cells and their progenitors - isolation, identification and colony growth (CFU-TL, CFU-BL). In: Methods in Hematology: Hematopoiesis. Ed. D.W. Golde, Churchill Livingstone, New York, p. 150, 1984.
  48. Roffman E., Sredni B., Smolinsky A. and Wilchek M. Chemical reduction of oxidize human lymphocytes inhibits interleukin 2 production but not induction of responsiveness. Proc. Natl. Acad. Sci. USA 81: 5209, 1984.
  49. Sredni B. and Rozenszajn L.A. Lymphocyte stem cells. In: Hematopoietic Stem Cells. Eds. D.W. Golde & F. Takaku. New York, Marcel Dekker, p. 148, 1985.
  50. Fishman P., Djaldetti M., Hart J. and Sredni B. Growth of human basophil lines derived from chronic myelocytic leukemia cells in vitro; ultrastructure and X-ray microanalyzed studies. Immunology 55(1): 105, 1985.
  51. Yehuda S., Sredni B. and Kalechman Y. Effects of DSIP, 5-HTP and serotonin on the lymphokine system: A preliminary study. Intern. J. Neuroscience 33: 185, 1987.
  52. *Sredni B., Caspi R.R., Klein A., Kalechman Y., Danzinger Y., Ben Ya'akov M., Tamari T., Shalit F. and Albeck M. A new immunomodulating compound (AS101) with potential therapeutic application. Nature 330: 173-176, 1987.
  53. Sredni B. and Albeck M. A new immunomodulating compound (AS101) with potential therapeutic application. Fed. Proc. 46: 1354, 1987.
  54. .Eisenstein Z., Engelsman E., Weiss M., Kalechman Y. and Sredni B. Production of and response to interleukin-2 in Graves' disease. J. Clin. Immunol. 8: 349-355, 1988.
  55. Sredni B., Caspi R.R., Lustig S., Klein A., Kalechman Y., Danziger Y., Ben Ya'akov M., Tamari T., Shalit F. and Albeck M. The biological activity and immunotherapeutic properties of AS101, a synthetic organotellurium compound. Nat. Immun. Cell Growth Regul. 7: 163-168, 1988.
  56. Albeck M., Tamari T. and Sredni B. A synthesis and properties of ammonium trichloro(dioxythylene-0,0')tellurate (AS101). A new immunomodulating compound. Synthesis 8: 635-6, 1989.
  57. Nyska A., Waner T., Pirak M., Albeck M. and Sredni B. Toxicity study in rats of a tellurium based immunomodulating drug, AS101: a potential drug for AIDS and cancer patients. Archives of Toxicology 63(5): 386-93,1989.
  58. Alcocer-Varela J., Alarcon-Segovia D., Sredni B. and Albeck M. Effect of the new immunoregulator AS101 on in vitro functions of mononuclear cells from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 77: 319, 1989.
  59. .Kalechman Y., Gafter U., Levi J., Sobelman D. and Sredni B. The effect of a single whole blood transfusion on cytokine secretion. J. Clin. Immunol. 10(2): 99-105, 1990.
  60. Michlin H., Schlesinger M., Kalechman Y. and Sredni B. Cell lines derived from human autorosette-forming cells with suppressive activity. Nat. Immun. Cell Growth Regul. 9(1): 49, 1990.
  61. Blank M., Sredni B., Albeck M., Mozes E. and Shoenfeld Y. The effect of the immunomodulator agent AS101 on IL-2 production in SLE disease induced in mice by a pathogenic anti-DNA antibody. Clin. Exp. Immunol. 79: 443, 1990.
  62. Sredni B., Kalechman Y., Shalit F. and Albeck M. Synergism between AS101 and PMA in lymphokine production. Immunology 69: 110-116, 1990.
  63. Sredni B., Catane R., Shani A., Gezin A., Levi E., Schlezinger M., Kalechman Y., Michlin H., Shalit F., Rosenzajn L.A., Farbstein H. and Albeck M. Phase I study of AS101 (an organotellurium compound) in patients with advanced malignancies. In: Recent Advances in Chemotherapy.
  64. Eds. E. Rubinstein and D. Adam. Jerusalem, E. Lewin-Epstein, 1990, pp. 851.1-851.4.
  65. Shani A., Tichler T., Catane , R., Gurwith M., Rozenszajn L.A., Gezin A., Levi E., Schlesinger M., Kalechman Y., Michlin H., Shalit F., Engelsman, E., Farbstein H., Farbstein M., Albeck M. and Sredni B. The immunologic effects of AS101 in the treatment of cancer patients. Nat. Immun. Cell Growth Regul. 9: 182-190,1990.
  66. Fishman P., Sredni B. and Djaldetti M. Recent advances in Interleukin-3 research: A Review. Israel J. Med. Sci. 26: 414-9, 1990.
  67. Kalechman Y., Sredni B., Caspi R.R. and Nussenblatt R.B. Enhancing effect of cyclosporins A and G on bone marrow colony formation. Exp. Hematol. 18(10): 1104-7, 1990.
  68. Sredni B., Kalechman Y., Albeck M., Gross O., Aurbach D., Sharon P., Sehgal S.N., Gurwith M.J. and Michlin H. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase-C inducer bryostatin. Immunology, 70(4): 473-7, 1990.
  69. Kalechman Y., Albeck M., Oron M., Sobelman D., Gurwith M., Sehgal S.N. and Sredni B. The radioprotective effects of the immunomodulator AS101. J. of Immunol. 145: 1512-7, 1990.
  70. Sredni B., Fishman P., Albeck M. Immunosuppression: New Chemical Immunomodulators. 1991 McGraw-Hill Yearbook of Science and Technology. New York, McGraw-Hill Inc., 1990,pp. 195-197.
  71. Djaldetti M., Fishman P., Shtatlender V. and Sredni B. Effect of Dexamethasone on IL-1 and IL-3-LA release by unstimulated human mononuclear cells. Biomed. & Pharmacother. 44: 515, 1990.
  72. In: Drugs of the Future. Vol. 15, No. 5, p. 511, 1990.
  73. Fishman P., Djaldetti M., Grossman S., Sofer Y. and Sredni B. Spontaneous release of a factor with interleukin-3-like activity by human lymphocytes and monocytes. Nat. Immun. Cell Growth Regul. 9: 341-41, 1990.
  74. Yron I., Langer A., Weinstein T., Sahar E., Lidor Y., Pardo Y., Katz I., Shohat L., Ovadia J., Kalechman Y., Ovadia J., Witz I.P., and Sredni B. Effect of sex hormones on human T cell activation by Concanvalin A. Nat. Immun. Cell Growth Regul. 10: 32-44, 1991.
  75. Fishman P., Sredni B. and Djaldetti M. The relationship between interleukin-3-like activity and basophil production in chronic myeloid leukemia patients. Immunology Letters, 28: 73-8, 1991.
  76. *Kalechman Y., Albeck M., Oron M., Sobelman D., Gurwith M., Horwith G., Kirsch T., Maida B., Sehgal S.N., Sredni B. Protective and restorative role of AS101 in combination with chemotherapy. Cancer Res. 51(5): 1499-1503, 1991.
  77. Kalechman Y., Michlin H., Gafter U. and Sredni B. Generation of cell lines with suppressive activity derived from autorosette forming cells of patients with autoimmune diseases. Annals of the New York Academy of Sciences 628: 373-378, 1991.
  78. Kalechman Y., Sotnik Barkai I., Albeck M., Horwith G., Sehgal S.N. and Sredni B. Use and mechanism of action of AS101 in protecting bone marrow CFU-GM after purging with ASTA-Z 7557. Cancer Res. 51(20): 5614-20, 1991.
  79. Gafter U., Kalechman Y., Sobelman D. and Sredni B. Induction of a subpopulation of suppressor cells by a single blood transfusion. Kidney Inter. 41(1): 143-148, 1992.
  80. Sredni B., Albeck M., Kazimirsky G. and Shalit F. The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent. Inter. J. of Immunopharmac. 14(4): 613-9, 1992.
  81. Kozenitzki L., David M., Sredni B., Albeck M. and Shohat B. Immunomodulatory effects of AS101 on Interleukin-2 production and T lymphocyte function of lymphocytes treated with psoralens and ultraviolet A. Photodermatol Photoimmunol. Photomed. 9: 24-28, 1992
  82. Bakimer R., Fishman P., Blank M., Sredni B., Djaldetti M. and Shoenfeld Y. Induction of Primary Anti-Phospholipid Syndrome in Mice by Immunization with a Human Monoclonal Anti-Cardiolipin Antibody (H-3): J. Clin. Invest. 89: 1558-1563, 1992.
  83. Vonsover A., Sredni B., Loya S., Horwith G., Kirsch T.M., Albeck M., Gotlieb-Stematsky T. and Hizi A. Inhibition of the reverse transcriptase activity and replication of human immunodeficiency virus type 1 by AS101 in vitro. AIDS Res. & Human Retro. 8(5): 613-23, 1992.
  84. Kalechman Y., Albeck M. and Sredni B. In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer Bryostatin. Cellular Immunol. 143(1): 143-53, 1992.
  85. Kalechman Y., Sotnik-Barkai I., Albeck M. and Sredni B. The effect of AS101 on the reconstitution of T cell reactivity following irradiation or cyclophosphamide treatment. Exp. Hematol. 20: 1302-8, 1992.
  86. Fishman P., Sredni B., Reznick R., Zigelman R., Djaldetti M. and Hart J. Cultured human cord blood cells spontaneously produce a factor with basophil-promoting activity. Immunol Lett 30(3): 189-193, 1992.
  87. Albeck M. and Sredni B. AS101 [Ammonium trichloro(dioxoethylene-0,0')tellurate] a new immunomodulator for use in treatment of malignancies and AIDS. In: Trends in Medicinal Chemistry, IUPAC, Blackwell Scientific Publications, Oxford, 90: 329-332, 1992
  88. Kalechman Y., Gafter U., Sotnik Barkai I., Albeck M., Gurwith M., Horwith G., Kirsch T., Maida B., Sehgal S.N., and Sredni B. Mechanism of radioprotection conferred by the immunomodulator AS101. Exp. Hematol. 21:150-5, 1993.
  89. Gafter U., Kalechman Y., Zevin D., Korzets A., Livni E., Klein T., Sredni B., and Levi J. Tubulo-Interstitial Nephritis and Uveitis: Association with suppressed cellular immunity. Nephrol Dial and Transplant 8:821-826, 1993.
  90. Kalechman Y., Sotnik-Barkai I., Albeck M., and Sredni B. Protection of bone marrow stromal cells from the toxic effects of Cyclophosphamide in vivo and of ASTA-Z 7557 and Etoposide in vitro by Ammonium trichloro(dioxyethylene-0-0')tellurate (AS101). Cancer Res. 53(8):1838-1844, 1993.
  91. Fishman P., Shoenfeld Y., Azizi E., Sredni B., Yecheskel G., Zigelman R., Floro S., and Djaldetti M. Vitiligo antibodies are effective against melanoma cells. Cancer 72: 2365-2389, 1993.
  92. Kalechman K., Herman S., Gafter U., and Sredni B. Enhancing effects of autologous erythrocytes on human or mouse cytokine secretion and IL-2R expression. Cell. Immunol. 148:114-129, 1993.
  93. Kalechman Y., Sotnik-Barkai I., Albeck M., and Sredni B. Increased DNA repair ability following irradiation after treatment with the immunomodulator AS101. Rad. Res. 136:197-204, 1993.
  94. Shohat B., Kozenitzki L., David M., Albeck M., and Sredni B. Effect of UVB and AS101 on Interleukin-2 production and helper activity in psoriatic patients. Nat. Immun. 12: 50-55, 1993.
  95. Fishman P., Falach-Vaknine E., Zigelman R., Bakiner R., Sredni B., Djaldetti M., and Shoenfeld Y. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of RIL-3. J. Clin. Invest. 91:1834-1837, 1993.
  96. Fishman P., Nedivi R., Djaldetti M., Sredni B., Kayzer S., and Chaimoff C. Kinetics of cortisol, IL-2 and IL-3-Like activity levels following surgical intervention. Nat. Immun. 12:35-40, 1993.
  97. *Kalechman Y., Shani A., Sotnik-Barkai I., Albeck M., and Sredni B. The protective role of Ammonium Trichloro(dioxoethylene-0,0')tellurate in combination with several cytotoxic drugs acting by different mechanisms of action. Cancer Res. 53: 5962-5969, 1993.
  98. Huberman M., Shalit F., Roth Deri I., Gutman B., Kott E., and Sredni B. Decreased IL-3 production by peripheral blood mononuclear cells in patients with multiple sclerosis. J. Neurological Sciences 118: 79-82, 1993.
  99. Sredni B., Albeck M., and Kalechman Y. Immunomodulation by AS101: mode of action and clinical applications in cancer therapy. In: The negative regulation of hematopoiesis. Ed. M. Guigon et al. Colloque INSERM/John Libbey Eurotext Ltd., 229, pp. 477-484, 1993.
  100. Gafter U., Kalechman Y., Orlin J.B., and Levi J., Sredni B. Anemia of uremia is associated with reduced cytokine secretion: immunopotentiating activity of red blood cells. Kidney International 45:224-231, 1994.
  101. Eisenstein Z., Engelsman E., Weiss M., Kalechman Y., and Sredni B. Modulation of the Interleukin-2 production defect in vitro in Graves' Disease. Clin. Exp. Immunol. 96: 323-328, 1994.
  102. Shalit F., Sredni B., Stern L., Kott E., and Huberman M. Elevated Interleukin-6 secretion levels by mononuclear cells of Alzheimer patients. Neuroscience Lett. 174: 130-132, 1994.
  103. Huberman M., Shalit F., Roth-Deri I., Gutman B., Brodie C., Kott E., and Sredni B. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J. Neuroimmunol. 52:147-152, 1994.
  104. Dastgheib K., Hikita N., Sredni B., Albeck M., Sredni D., Nussenblatt R.B., and Chan C. Ocular inflammation stimulated by the immunomodulator AS101 [ammonium trichloro(dioxyethelene-O-O') tellurate]. Curr. Eye Res. 13:603-610, 1994.
  105. Sredni B., Rosenthal Z., Michlin H., Sobelman D., Segev Y., Blagerman S., Albeck M.,
    Kalechman Y., and Rager-Zisman B. Restoration of murine cytomegalovirus (MCMV) induced myelosuppression by AS101. Immun Letters 43:159-165, 1994.
  106. Sredni B., Albeck M., and Kalechman Y. The immunomodulating and therapeutic properties of AS101. In: Forum on Immunomodulators. M. Guenounou (Ed.) John Libbey Eurotext, Paris, 1995, pp. 123-146.
  107. Kalechman Y., Shani A., Albeck M., and Sredni B. Induction of acute phase proteins in mice and humans by treatment with AS101, an immunomodulator with radioprotective properties. Immunopharmacology 29:149-158, 1995.
  108. Kalechman Y., Zuloff A., Albeck M., Strassmann G., and Sredni B. Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator AS101. Blood 85:1555-1561, 1995.
  109. Fishman P., Falach-Vaknin E., Sredni B., Meroni L., and Shoenfeld Y. Aspirin modulates Interleukin-3 production: Additional explanation for the preventive effects of Aspirin in anti-phospholipid syndrome. J. Rheumatol. 22:1086-1090, 1995.
  110. *Sredni B., Albeck M., Tichler T., Shani A., Shapira J., Bruderman I., Catane R., Kaufman B., and Kalechman Y. Bone marrow sparing and prevention of alopecia by AS101 in NSCL cancer patients treated with carboplatin and etoposide. J. Clin. Oncol. 13:2342-2353, 1995.
  111. Xu R., Kalechman Y., Albeck M., and Sredni B. Cytoprotective effect of the immunomodulator AS101 against hydrochloride induced gastric lesions. Research Communications in Molecular Pathology & Pharmacology 87:4-20, 1995.
  112. Kalechman Y., Lederer G., Nerubay J., Albeck M., and Sredni B. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia and erythropenia in mice. Exp. Hematol. 23:1358-1366, 1995
  113. Shalit F., Sredni B., Brodie C., Kott E., and Huberman M. T lymphocyte subpopulations and activation as a marker for severity of Alzheimer's disease. Clinical Immunology and Immunopathology 75:246-250, 1995.
  114. Huberman M., Sredni B., Stern L., Kott, E. and Shalit F. IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease. J. Neurol. Sci. 130:161-164, 1995.
  115. Mittwoch-Jaffe T., Shalit F., Sredni B., and Yehuda S. Modification of cytokine secretion following mild emotional stimuli. Neuroreport. 6:789-792, 1995.
  116. Sredni B., Xu R.H., Albeck M., Gafter U., Gal R., Shani A., Tichler T., Shapira J., Bruderman I., Catane R., Kaufman B., Whisnant J.K., Mettinger K.L., and Kalechman Y. The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia. Studies on human and animal models. Int. J. Cancer 65:97-103, 1996.
  117. Herman S., Kalechman Y., Gafter U., Sredni B. and Malik A. Photofrin II induces cytokine secretion by mouse spleen cells and human peripheral mononuclear cells. Immunopharmacology 31:195-204, 1996.
  118. Kalechman Y., Shani A., Dovrat S., Whisnant J.C., Mettinger K., Albeck M., Bruckner H.W., and Sredni B. Synergistic antitumor effect of the immunomodulator AS101 and taxol in experimental murine models. J Immunol 156: 1101-1109, 1996.
  119. Xu R.H., Kalechman Y., Albeck M., Kung H.F. and Sredni B. Inhibition of B16 melanoma metastasis by the immunomodulator AS101. Int J Oncol 9:319-325, 1996.
  120. Rosenblatt-Bin H., Klein A. and Sredni B. The effect of the immunomodulalor AS101 on mice infected with Babesia Rodhaini. Parasite Immunology 18: 297-306, 1996.
  121. Sredni B., Tichler T., Shani A., Catane R., Kaufman B., Strassman G., Albeck M., and Kalechman Y. Predominance of TH1 response in tumor bearing mice and cancer patients treated wtih AS101. JNCI (Journal of the National Cancer Institute) 88(18): 1276-1284, 1996.
  122. Kalechman Y. and Sredni B.  Differential Effect of the immunomodulator AS101 on B7-1 and B7-2 Costimulatory Molecules: Role in the Antitumoral Effects of AS101. J Immunol 157:589-597, 1996.
  123. Gafter U., Kalechman Y. and Sredni B. Blood transfusion enhances production of T-helper-2 cytokines and transforming growth factor b in humans. Clinical Science 91: 519-523, 1996.
  124. Gafter U., Sredni B., Segal J. and Kalechman Y. Suppressed cell-mediated immunity, monocyte and Natural Killer cell activity following allogeneic immunization of women with spontaneous recurrent abortions. J. Clin. Immunol 17:408-419, 1997.
  125. *Kalechman Y., Gafter U., Da J.P., Albeck M., Alarcon-Segovia D. and Sredni B. Delay in the onset of Systemic Lupus Erythematosus following treatment with the immunomodulator AS101. J. Immunol. 159:2658-2667, 1997.
  126. Shalit F., Sredni B., Rosenblatt-Bin H., Brodie C., Huberman M. Beta amyloid peptide induces tumor necrosis factor-a and nitric oxide production in murine macrophage cultures. Neuroreport 8:3577-3580, 1997.
  127. Rosenblatt-Bin H., Kalechman Y., Vonsover A., Xu R-H., Da J-P., Shalit F., Klein A., Albeck M., and Sredni B. The immunomodulator AS101 restores Th1 type of response suppressed by Babesia Rodhaini in BALB/c mice. Cell Immunol. 184:12-25, 1998.
  128. Kalechman Y., Strassmann G., Albeck M. and Sredni B. Up-regulation by Ammonium Trichloro(Dioxoethylene-0,0')Tellurate (AS101)  of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101.  J Immunol 161:3536-3542, 1998.
  129. 128.Albeck A., Weitman H., Sredni B. and Albeck M. Tellurium compounds: selective inhibition of Cysteine proteases and model reaction with Thiols. Inorg. Chem. 37: 1704-1712, 1998.
  130. Geffen R., Shalit F., Sredni B. And Yadid G. Immunomodulation as a Treatment for Parkinson's Disease. Neuroscience Letters, p.S17, 1999.
  131. Kalechman Y., Longo D.L., Catane R., Shani A., Albeck M. and Sredni B. Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal transduction pathways. Int. J. Cancer 86: 281-288, 2000
  132. Dagon, Y., Dovrat, S., Vilchik, S., Hacohen, D., Shlomo, G., Sredni, B., Salzberg, S. and Nir, U. Double-stranded RNA-dependent protein kinase, PKR, down-regulates CDC2/cyclin B1 and induces apoptosis in non-transformed but not in v-mos transformed cells. Oncogene 20: 8045-8056, 2001.
  133. 132.Shohat M, Hodak E, Sredni B, Shohat B, Sredni D and David M. Cytokine profile of patients with mycosis fungoides and the immunomodulatory effect of AS101. Acta Derm Venereol. 81: 255-257, 2001.
  134. .Kalechman Y., Gafter U., Gal R., Rushkin G., Yan D., Albeck, M. and Sredni B. (2002) Anti IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. J. Immunol. 169: 384-392, 2002.
  135. Bouganim, M., Kalechman, Y., Albeck, M. and Sredni, B. The Synergistic Activity of AS101 and PMA on HL-60 Cells Differentiation: Mechanism of Action. 2002 Proceedings. Tumor Microenvironment Progression, Therapy, Prevention, 2002.
  136. Gafter-Gvili A, Sredni B, Gal R, Gafter U, Kalechman Y. Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes. Am J Physiol Cell Physiol. 284: C1593-C1603, 2003.
  137. Kalechman Y., Sredni B., Weinstein T., Freidkin I., Tobar A., Albeck M. and Gafter U. Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101. J Am Soc Nephrol 14: 620-630, 2003.
  138. Sredni B., Yadid G., Albeck M., Shalit F., Geffen R. A novel treatment for Parkinson's Disease using an Immunomodulator. J of Neurochemistry 85: 90, 2003.
  139. Sinnuani I., Gitelman I., Averbukh Z., Kalechman Y., Sredni B. And Weissgarten J. P57kip2 is Pivotal Factor in Compensatory Tubular Cell Atrophy. J Amer Soc Nephrol, Vol 14, P. 328A, 2003.
  140. Makarovsky D, Kalechman Y, Sonino T, Freidkin I, Teitz S, Albeck M, Weil M, Geffen-Aricha R, Yadid G, Sredni B. Tellurium compound AS101 induces PC12 differentiation and rescues the neurons from apoptotic death. Ann. N.Y. Acad. Sci. 1010: 659-666, 2003.
  141. Sredni B., Gal R., Cohen    IJ., Dazard, JE., Givol, D. Gafter U., Motro B., Eliyahu S., Albeck M., Lander HM., and Kalechman Y. Hair growth induction by the Tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes  and  ras-dependent up-regulation of KGF expression. FASEB J. 18: 400-402, 2004.
  142. Sredni B., Eliahu S., Gal R., Gafter U., Motro B., Albeck M., Lander H., Cohen    I., and Kalechman Y. Hair growth induction by The Tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes  and  ras-dependent upregulation of KGF expression. FASEB18: 400-402, 2004.
  143. Sredni B., Weil M., Khomenuk G., Lebenthal I., Teitz S., Mardor Y., Ram Z., Orenstein A., Kershenovich A., Michowiz S., Cohen Y.I., Rappaport Z.H., Freidkin I., Albeck M., Longo DL and Kalechman Y. Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting tumor IL-10 autocrine loop. Cancer Res. 64:1843-1852, 2004.
  144. Kalechman Y, Gafter U, Weinstein T, Chagnac A, Freidkin I, Tobar A, Albeck M, Sredni B. Inhibition of IL-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis: Association with dephosphorylation of STAT3. J Biol Chem. 279: 24724-24732, 2004.
  145. Gafter-Gvili, A., Kalechman, Y., Sredni, B., Gal, R., and Gafter, U. Cyclosporin A-induced hair growth in mice is associated with inhibition of hair follicle regression. Arch. Dermatol. Res 296: 265-269, 2004.
  146. Shohat, M., Mimouni, D., Ben Amitai, D., Sredni, B., Sredni, D., Shohat, B., and David, M. In vitro cytokine profile in childhood alopecia areata and the immunomodulatory effects of AS-101. Clin. Exp. Dermatol. 30: 432-434, 2005.
  147. Dror M, Sinyakov MS, Okun E, Dym M, Sredni B and Avtalion RR Experimental handling stress as infection-facilitating factor for the goldfish ulcerative disease. Vet Immunol Immunopathol. 109: 279-287, 2006.
  148. Okun E, Saida H, Albeck M, Sredni B and Avtalion RR Upregulation of carp GDNF mRNA by the immunomodulator AS101. Dev Comp Immunol. 30: 441-446, 2006.
  149. Sinuani, I., Averbukh, Z., Gitelman, I., Rapoport, M. J., Sandbank, J., Albeck, M., Sredni, B. and Weissgarten, J. Mesangial cells initiate compensatory renal tubular hypertrophy via IL-10 induced TGF- secretion: Effect of the immunomodulator AS101 on this process. Am. J. Physiol. Renal Physiol. 291: F384-F394 2006.
  150. Snir, O., Lavie, G., Achiron, A., Bank, I., Ben Aharon, T., Sredni, B., Cohen, I. R., and Mandel, M. G-CSF enhances the adhesion of encephalitogenic T cells to extracellular matrix components: a possible mechanism for exacerbation of multiple sclerosis J. Neuroimmunol. 172, 145-155, 2006.
  151. Hayun M, Naor Y, Weil M, Albeck M, Peled A, Don J, Haran-Ghera N, Sredni B. The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway. Biochem Pharmacol. 72(11):1423-1431 2006.
  152. Sredni B, Geffen-Aricha R, Duan W, Albeck M, Shalit F, Lander HM, Kinor N, Sagi O, Albeck A, Yosef S, Brodsky M, Sredni-Kenigsbuch D, Sonino T, Longo DL, Mattson MP, Yadid G. Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models. FASEB J. 21(8): 1870-1883, 2007.
  153. Okun E, Dikshtein Y, Carmely A, Saida H, Frei G, Sela BA, Varshavsky L, Ofir A, Levy E, Albeck M, Sredni B. The organotellurium compound ammonium trichloro(dioxoethylene-o,o')tellurate reacts with homocysteine to form homocystine and decreases homocysteine levels in hyperhomocysteinemic mice. FEBS J. 274(12): 3159-3170 2007
  154. Hayun R, Shpungin S, Malovani H, Albeck M, Okun E, Nir U, Sredni B. Novel involvement of the immunomodulator AS101 in IL-10 signaling, via the tyrosine kinase Fer. Ann N Y Acad Sci. 1095: 240-250 2007.
  155. Grinberg, O., Hayun, M., Sredni, B., and Gedanken, A. Characterization and activity of sonochemically-prepared BSA microspheres containing Taxol - an anticancer drug. Ultrason. Sonochem. 14: 661-666 2007.
  156. Hayun M, Okun E, Hayun R, Gafter U, Albeck M, Longo DL, Sredni B. Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model. Leukemia 21(7): 1504-1513 2007.
  157. Israeli, M., Yussim, A., Mor, E., Sredni, B., and Klein, T. Preceding the rejection: In search for a comprehensive post-transplant immune monitoring platform. Transpl. Immunol. 18: 7-12 2007.
  158. Brodsky, M., Yosef, S., Galit, R., Albeck, M., Longo, D. L., Albeck, A., and Sredni, B. The synthetic tellurium compound, AS101, is a novel inhibitor of IL-1beta converting enzyme. J. Interferon Cytokine Res. 27: 453-462 2007.
  159. Yosef, S., Brodsky, M., Sredni, B., Albeck, A., and Albeck, M. Octa-O-bis-(R,R)-Tartarate Ditellurane (SAS)-a novel bioactive organotellurium (IV) compound: Synthesis, characterization, and protease inhibitory activity. ChemMedChem. 2: 1601-1606, 2007.
  160. Frei, G. M., Lebenthal, I., Albeck, M., Albeck, A., and Sredni, B. Neutral and positively charged thiols synergize the effect of the immunomodulator AS101 as a growth inhibitor of Jurkat cells, by increasing its uptake. Biochem. Pharmacol. 74: 712-722, 2007.
  161. Arumugam TV, Gleichmann M, Sredni B, Frei GM, Hanschmann KM, Albeck M, Schnierle BS. Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101 Br J Dermatol. 158: 578-586, 2008.
  162. Israeli M, Klein T, Sredni B, Avitzur Y, Mor E, Bar-Nathen N, Steinberg R, Dinari G and Shapiro R. ImmuKnow: A new parameter in immune monitoring of pediatric liver transplantation recipients. Liver Transpl. 2008 May 28;14(6):893-898.
  163. Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman    B, Koeffler HP, Rubinek T. Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene. 2008; 27(56):7094-105.
  164. Friedman M, Bayer I, Letko I, Duvdevani R, Zavaro-Levy O, Ron B, Albeck M. and Sredni B. Topical treatment for human papillomavirus-associated genital warts in humans with the novel tellurium immunomodulator AS101: assessment of its safety and efficacy. Br J Dermatol. 2009;160 (2):403-8.
  165. Sinuani I, Weissgarten J, Beberashvili1 I, Rapoport MJ, Sandbank J, FeldmanL, Albeck M, Averbukh Z and Sredni B. The cyclin kinase inhibitor p57kip2 regulates TGF-β-induced compensatory tubular hypertrophy: effect of the immunomodulator AS101. Nephrol Dial Transplant. 2009 Mar 25. [Epub ahead of print]
  166. Hayun R, Okun E, Berrebi A, Shvidel L, Bassous L, Sredni B, Nir U. Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. Leuk Lymphoma. 2009 Apr;50(4):625-32
  167. Hayun M, Saida H, Albeck M, Peled A, Haran-Ghera N   and Sredni B. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model Exp Hematol. 2009 May; 37(5):593-603
  168. Yehuda S, Sredni, B, Carasso, RL and Kenigsbuch-Sredni D. REM sleep deprivation in rats results in   inflammation and IL-17 elevation. J Interferon & Cytokine Research. 2009 May 18.
  169. Carmely A, Meirow D, Peretz A, Albeck M, Bartoov B, Sredni B. Protective effect of the  immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice Hum Reprod. 2009; 24(6):1322-9.
  170. Vardi A, Anikster Y, Eisenkraft A, Shohat M, Abu-Much J, Eisenkraft S, Sredni B, Nir U. A new genetic isolate of acrodermatitis enteropathica with a novel mutation. Br J Dermatol. 2009 Apr 16.
  171. Brodsky M, Hirsh S, Albeck M, Sredni B. Resolution of inflammation-related apoptotic processes by   the synthetic tellurium compound AS101 following liver injury. J Hepatol. 2009 Sep; 51(3):491-503.
  172. Daniel-Hoffmann M, Albeck M, Sredni B, Nitzan Y.A potential antimicrobial treatment against  ESBL-producing Klebsiella pneumoniae using the tellurium compound AS101.Arch Microbiol. 2009 Aug; 191(8):631-8.
  173. Brodsky M, Hirsh S, Albeck M, Sredni B. Resolution of inflammation-related apoptotic processes by   the synthetic tellurium compound, AS101 following liver injury. J Hepatol. 2009 Sep; 51(3):491-503.
  174. Israeli M, Ben-Gal T, Yaari V, Valdman A, Matz I, Medalion B, Battler A, Sredni B, Kristt D, Klein T. Individualized Immune Monitoring of Cardiac Transplant Recipients by Noninvasive Longitudinal Cellular Immunity Tests. Transplantation. 2010 Jan 13. [Epub ahead of print]
  175. Brodsky M, Halpert G, Albeck M, and Sredni B. The anti-inflammatory effects of the tellurium redox modulating compound, AS101, are associated with regulation of NFkappaB signaling pathway and nitric oxide induction in macrophages. Journal of Inflammation 2010, 7:3.
  176. Sredni B. Immunomodulating Tellurium compounds as anti-cancer agents. Semin Cancer Biol. 2012  Feb; 22(1):60-9.
  177. Sredni B., Longo DL. Cancer Immunotherapy: Are we there yet? . 2011 2012  Feb; 22(1):1-2.
  178. Indenbaum V, Bin H, Makarovsky D, Weil M, Shulman LM, Albeck M and Sredni B. In vitro and in vivo activity of As101 against West Nile Virus (WNV). Virus Res. 2012
  179. Derech-Haim S, Teiblum G, Kadosh R, Rahav G, Bonda E, Sredni B and Bakhanashvili M. Ribonuclease activity of p53 in cytoplasm in response to various stress signals. Cell  Cycle, 2012 Apr 1;11(7):1400-13.
  180. Bactericidal activity of the organo-tellurium compound AS101 against Enterobacter cloacae.
  181. Israeli M, Sredni B, Mor E, Zakai C, Tadmor B and Klein T. The immune-modulator AS101 reduces anti-HLA antibodies in sera of sensitized patients: A structural approach. Int Immunopharmacol. 2012 Jun 7;13(4):483-489.
  182. Naor Y., Hayun M., Sredni B. and Don J.  Multiple signal transduction pathways are  involved in G2/M growth arrest and apoptosis induced by the immunomodulator AS101 in multiple myeloma. . 2013
  183. Halperin M., Gertler A., Okun E., Sredni B., Cohen H. The Tellurium Compound, AS101, Increases SIRT1 Level and Activity and Prevents Type 2 Diabetes. Aging Journal, 2012 Jun;4(6):436-47.
  184. Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility. Science Translational Medicine journal. 2013 May 15;5(185):185ra62
  185. Ling D, Liu B, Jawad S, Thompson IA, Nagineni CN, Dailey J, Chien J, Sredni B, Nussenblatt RB. The tellurium redox immunomodulating compound AS101 inhibits IL-1β-activated inflammation in the human retinal pigment epithelium.
  186. Cellular immune function monitoring after allogeneic haematopoietic cell transplantation: evaluation of a new assay.
  187.  Lee JH, Halperin-Sheinfeld M, Baatar D, Mughal MR, Tae HJ, Kim JW, Carter A, Lustig A, Snir O, Lavie G, Okun E, Mattson MP, Sredni B, Taub DD. Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNS. . 2014 Jun;16(2):292-307
  188. Yalew R, Kenigsbuch-Sredni D,Sredni B, Nitzan Y. Antibacterial effects of the tellurium compound OTD on E. coli isolates. . 2014 Jan;196(1):51-61
  189. Layani-Bazar A, Skornick I, Berrebi A, Pauker MH, Noy E, Silberman A, Albeck M, Longo DL, Kalechman Y,Sredni B. Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state. . 2014 Jun 1;74(11):3092-103
  190. Halpert G, Eitan T, Voronov E, Apte RN, Rath-Wolfson L, Albeck M, Kalechman Y, Sredni B. Multifunctional Activity of a Small Tellurium Redox Immunomodulator Compound, AS101, on Dextran Sodium Sulfate-induced Murine Colitis. . 2014 Jun 13;289(24):17215-17227.
  191. Xie L, Chen J, McMickle A, Awar N, Nady S, Sredni B, Drew PD, Yu S. The immunomodulator AS101 suppresses production of inflammatory cytokines and ameliorates the pathogenesis of experimental autoimmune encephalomyelitis. . 2014 Aug 15;273(1-2):31-41.
  192. .Halpert G,Sredni B. The effect of the novel tellurium compoundon autoimmune diseases. Autoimmun Rev.2014 Aug 19. pii: S1568-9972(14)00147-5.
  193. .Danoch HKalechman YAlbeck MLongo DLSredni BMol Cancer Res
  194. .AS101 Prevents Diabetic Nephropathy Progression and Mesangial Cell Dysfunction: Regulation of the AKT Downstream Pathway. Shemesh II, Rozen-Zvi B, Kalechman Y, Gafter U, Sredni B. PLoS One. 2014 Dec 4;9(12):e114287
  195. MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome. Shaham L, Vendramini E, Ge Y, Goren Y, Birger Y, Tijssen MR, McNulty M, Geron I, Schwartzman O, Goldberg L, Chou ST, Pitman H, Weiss MJ, Michaeli S, Sredni B, Göttgens B, Crispino JD, Taub JW, Izraeli S. Blood. 2015 Feb 19;125(8):1292-301.
  196.  The immunomodulator, ammonium trichloro[1,2-ethanediolato-O,O']-tellurate, suppresses the propagation of herpes simplex virus 2 by reducing the infectivity of the virus progeny. D. Sheinboim, M. Hindiyeh, E. Mendelson, M. Albeck, B. Sredni, S. Dovrat. Int J Mol Med. 2015 Apr 24. doi: 10.3892/ijmm.2015.2197. [Epub ahead of print]

 

 

Registered Patents:

  1. Djaldetti M., Sredni B., Fishman P. and Grossman S: Extraction of Lymphokines - Isolation of   Natural Human Interleukin-3. Israel Patent No. 04469 I-1051, 1986.
  2. Djaldetti M., Sredni B., Fishman P. and Grossman S: Receptors - Characterization and Isolation of Receptors of Human Interleukin-3. Israel Patent No. 04528 I-1051, 1986.
  3. Albeck M. and Sredni B: Pharmaceutical compositions of Tellurium and Selenium compounds for the induction of in vivo and in vitro production of Cytokines. Patent No. 4,752,614. United States Patent , June 21, 1988.
  4. Albeck M. and Sredni B: Organic derivatives of Tellurium and Selenium and their use to stimulate Cytokine production. Patent No. 4,761,490. United States Patent, Aug. 2, 1988.
  5. Albeck M. and Sredni B: Tellurium and Selenium compounds for the induction of in vivo and in vitro production of Cytokines. Patent No. 4,764,461. United States Patent, Aug. 16, 1988.
  6. Djaldetti M., Sredni B., Fishman P. and Grossman  S: Isolation of Lymphokines. U.S.A. Patent No. 05984 I-1077, 1988.
  7. Djaldetti M., Sredni B., Fishman P. and Grossman S: Anti-Metastatic Factor Derived from Muscle Cultures. Israel Patent No. 08597 I-1072, 1989.
  8. Sredni B., Pavliv L. Albeck M: Complexes of Tellurium and Selenium derivatives. U.S.A. Patent No. 4,929,739, May 29, 1990.
  9. Sredni B. and Albeck M: Method for the stimulation of bone marrow cells. United States Patent No. 4,946,437, Aug. 7, 1990.
  10. Albeck M. and Sredni B: Organic derivatives of Tellurium and Selenium. United States Patent No. 4,962,207, Oct. 9, 1990.
  11. Albeck M. and Sredni B: Compounds for the induction of in vivo and in vitro production of cytokines. U.S.A. Patent No. 5,093,135, March 3, 1992.
  12. Sredni B. and Albeck M: Method of inducing the production of cytokines. U.S.A. Patent No. 5,126,149, June 30, 1992.
  13. Sredni B. and Albeck M: Method of treating or preventing alopecia. Patent No. 5,262,149. United States Patent, Nov. 16, 1993.
  14. Sredni B., Huberman M., and Shalit F. Diagnosis of Alzheimer disease stage by mononuclear cell cytokine secretions. 081257, 740. United States, 1994.
  15. The effect of as101 on male fertility. Filing Date. 01-Aug-2009. Application No. 61/193,916
  16. Methods and compositions for inhibiting integrins using tellurium-containing compounds. Filing Date 23-Nov-2008. Application No – pending
  17. Method and composition for reducing tumor development with a combination of platinum and tellurium of selenium compounds. Filing Date 12-Dec-1995 and 12-Dec-1995. Application No. 95944080.1 and 519175/1996
  18. Tellurium containing product. Filing Date 26-Jul-2002. Application No. 2,456,082
  19. Biologically active complex. Filing Date Israel 22-Nov-2001; Europe 24-Nov-2002; Canada 24-Nov-2002; USA 24-Nov-2002. Application No. 146694; 02779867.7; 2,467,926; 11/898,290
  20. Methods of treating obesity and related disorders using tellurium and selenium compounds. Filing Date USA, 13-Jun-2004; Europe, 13-Jun-2004; Israel, 13-Jun-2004. Application No. 10/560,232; 04736726.3; 172501
  21. Therapeutic methods and pharmaceutical compositions for treating warts with tellurium compounds. Filing Date Israel, 23-Jan-2005; Japan, 23-Jan-2005. Application No. 176876; 2006-550485
  22. Tellurium derivatives for prevention and treatment of neurodegenerative processes. Filing Date Canada, 15-Dec-2004; Europe, 15-Dec-2004; India, 15-Dec-2004; Australia, 15-Dec-2004; New Zealand, 15-Dec-2004; Israel, 15-Dec-2004; Japan, 15-Dec-2004. Application No. 2,550,459; 04801399.9; 2606/CHENP/2006; 2004304716; 548421; 176333; 2006-544590
  23. Use of tellurium containing compounds as nerve protecting agents. Filing Date USA, 15-Sep-2005; Application No. 11/226,374;
  24. Novel tellurium compounds and their use as immunomodulators. Filing Date USA, 15-Sep-2005; Europe, 15-Sep-2005; Hong Kong 15-Sep-2005; Canada, 15-Sep-2005; Israel, 15-Sep-2005. Application No. 11/663,031; 05779419.0; 07111672.5; 2,580,642; 181913
  25. Use of tellurium compounds for inhibition of interleukin-converting enzyme. Filing Date Europe, 15-Sep-2005; Hong Kong, 15-Sep-2005; Canada, 15-Sep-2005; Israel, 15-Sep-2005; USA, 15-Sep-2005. Application No. 05779639.3, 07112637.7; 2,580,643; 181914; 11/663,032
  26. Use of tellurium compounds as adjuvants. Filing Date USA, 15-Sep-2005; Canada, 15-Sep-2005. Application No. 11/662,954; 2,580,805
  27. Compositions and methods for inducing hair growth. Filing Date USA, 15-Sep-2005; Europe, 15-Sep-2005; Hong Kong, 15-Sep-2005; Canada, 15-Sep-2005; Japan, 15-Sep-2005; Australia 15-Sep-2005; New Zealand, 15-Sep-2005. Application No 11/662,743; 05784166.0; 07111673.4; 2,580,804; 2007-531953; 2005283719; 554380
  28. Use of tellurium compounds for protection from ultra-violet radiation. Filing Date USA, 14-Sep-2006; Europe, 14-Sep-2006; Canada, 14-Sep-2006; Australia, 14-Sep-2006; Israel, 14-Sep-2006. Application No. 11/992,094; 06796089.8; 2,619,073; 2006290297; 190126
  29. Topical formulations of tellurium-containing compounds. Filing Date Israel, 1 / 9/2006. Application No. 11.09.2007